谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

Suboptimal Outcomes of Sorafenib As a Second-Line Treatment after Atezolizumab-Bevacizumab for Unresectable Hepatocellular Carcinoma

Francesco Tovoli,Dante Pio Pallotta,Caterina Vivaldi,Claudia Campani,Piera Federico,Andrea Palloni,Andrea Dalbeni,Caterina Soldà,Lorenzo Lani,Gianluca Svegliati-Baroni,Ingrid Garajova,Luca Ielasi,Stefania De Lorenzo,Alessandro Granito,Bernardo Stefanini,Gianluca Masi,Fabio Marra,Sara Lonardi,Giovanni Brandi, Bruno Daniele

Digestive and Liver Disease（2024）

引用 0|浏览4
暂无评分
关键词
Hepatocellular carcinoma,Sorafenib,Immunotherapy,Tyrosine kinase inhibitors,Outcome
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要